Category: Bioinformatics |
| +  Scansite: A World-Wide-Web Interfaced Bioinformatic Computer Program to Predict Sites of Protein-Protein Interaction and Protein Phosphorylation (BIDMC 245) |
Category: Diagnostics/Biomarkers |
| +  Diagnostic test for epithelial cancers, including endometrial, based on serum levels of adiponectin and associated therapeutic compounds (BIDMC 715)
|
| +  Non-invasive Assessment of Therapeutic Toxicity and Efficacy from Physiologic Measurements (BIDMC 895) |
| +  Novel ECG-based Method for Identification of Ischemia-Induced Precordial T-Wave Inversions (BIDMC 817) |
| +  Rapid Anthrax Diagnosis & Treatment (BIDMC 1136) |
Category: Drug Delivery |
| +  Targeting Endothelium for Tissue-Specific Delivery of Therapeutic Agents (BIDMC 181)
|
| +  Wortmannin Conjugates and Uses Thereof (BIDMC 952) |
Category: Drug Discovery Tools |
| +  A New Optics-based Quantitative Method for Assessment of RBC Flickering (BIDMC 1049) |
| +  Anti-Angiogenic Properties of Type 1 Repeats of Thrombospondin 1 (TSP repeat) (BIDMC 402)
|
| +  Dual Anti-Proliferative and Pro-Apoptotic Functions of A20 in Smooth Muscle Cells (BIDMC 301) |
| +  NERF and ELF-1 as Novel Transcriptional Mediators of Angiogenesis and Therapeutic Drug Targets (BIDMC 541)
|
| +  Novel Telomerase Inhibitors and Uses Thereof (BIDMC 618)
|
| +  Role of Ghrelin in Intestinal Bowel Disorders (BIDMC 741) |
| +  The use of RTEF-1, a novel VEGF stimulator, for the treatment of abnormal angiogenesis (BIDMC 799) |
| +  Use of Platelet Derived Growth Factor Receptor Inhibitors for The Treatment of Vascular Access Dysfunction (BIDMC 696) |
Category: Foods and Plant Sciences |
| +  Dietary Formulation Comprising Arachidonic Acid and Methods of Use (BIDMC 351)
|
Category: Medical Devices |
| +  Novel Percutaneous Valve Repair System (BIDMC 1058) |
| +  Pericardial Reinforcement Device (BIDMC 950) |
| +  Tissue Transplant and Regeneration Device and Method to Treat Ischemic Heart Disease (BIDMC 960)
|
| +  Transatrial Catheter Access for Pericardial Space (BIDMC 191) |
Category: Medical Imaging |
| +  Arterial Spin Labeling Using Time Varying Gradients for Enhanced Fluid-Flow Imaging (BIDMC 634) |
| +  Charge-Coupled Devices for Wavelength-Selective Imaging (BIDMC 707) |
| +  Continuous Arterial Spin Labeling with Pulsed Radiofrequency Sequences for Enhanced Fluid-Flow Imaging (BIDMC 958) |
| +  Imaging of Cancer via Intraoperative Coded Aperture Radioscintigraphy (BIDMC 717) |
| +  Medical Imaging System and Contrast Agents (BIDMC 681) |
| +  Near-Infrared Fluorescent Albumin for Intraoperative Imaging (BIDMC 815) |
| +  Near-Infrared Fluorescent Fibrinogen for Optical Imaging of Thrombosis and Hemorrhage (BIDMC 872) |
| +  Noise Reduction System and Methods for Magnetic Resonance Imaging (BIDMC 1107) |
| +  Radio Frequency Impedance Mapping for Medical Imaging (BIDMC 701) |
| +  Simultaneous Acquisition of Spatial Harmonics (SMASH): Ultra-Fast Imaging with Radiofrequency Coil Arrays (BIDMC 354) |
| +  Solid-Phase Conversion of Tc-99m Pertechnetate to a Reactive N-Hydroxysuccinimide Ester (BIDMC 947) |
Category: Research Reagents |
| +  Human monoclonal antibody against desmoglein 3 (clone PVMAB786) (BIDMC 1341) |
| +  Human monoclonal antibody against HIV gp120 (clones F223, F424, F425A1, F425B4A1g8, F425B4e8) (BIDMC 1303) |
| +  Monoclonal antibodies against human Fc epsilon receptor (clones 15/1, 3G6, 4H7.1) (BIDMC 1294) |
| +  Monoclonal antibodies against human SAP (BIDMC 1324) |
| +  Monoclonal antibodies against human SPDEF (BIDMC 1340) |
| +  Monoclonal antibodies against mouse CD39 (clones 3C1 and 5F2) (BIDMC 1211) |
| +  Monoclonal antibodies against mouse LY108 (clones 13G3-19D and 330-AJ) (BIDMC 1314) |
| +  Monoclonal antibodies against mouse SAP (BIDMC 1323) |
| +  Monoclonal antibodies against mouse SLAM (BIDMC 1296) |
| +  Monoclonal antibodies against rat CD81 (BIDMC 1321) |
| +  Polyclonal Antibodies against TRMP4 (BIDMC 1319) |
| +  Rat basophilic leukemia cells expressing human FcεRI α-, ß- and γ-chains (known as RBL-SX38 cell line) (BIDMC 1293) |
Category: Research Tools |
| +  An Inducible/Reversible Transgenic Mouse Model of BCR/ABL Leukemia (BIDMC 133) |
| +  beta-1,2,3 adrenergic receptor triple knockout mouse (BIDMC 1311) |
| +  Melanocortin 4 receptor knockout mice (loxTB-MC4R mice) (BIDMC 1316) |
| +  Transcriptionally-disrupted orexin receptor mice (loxTD-OX1R and loxTD-OX2R mice) |
| +  Transgenic Animals Deficient in Endogenous beta-3 Adrenergic Receptor and Uses Thereof (BIDMC 335) |
| +  Transgenic mice expressing human FcEpsilon Receptor (BIDMC 1318) |
| +  Transgenic mice expressing the cre gene in POMC neurons (BIDMC 1315) |
| +  Transgenic Non-Human UCP2 Knockout Mouse (BIDMC 328) |
Category: Software/Algorithms |
| +  Pulse Sequence for Positive Contrast in MRI CEST (BIDMC 1180) |
Category: Therapeutics - Drugs |
| +  Anti-platelet Compounds that Inhibit Thrombosis by Selective G-protein Modulation (BIDMC 622)
|
| +  Compounds that Increase Insulin Secretion (BIDMC 745) |
| +  Inhibition of graft failure, using MARCKS siRNAs (BIDMC 899) |
| +  Methods and Compositions for the Treatment and Diagnosis of Statin-Induced Myopathy (BIDMC 1015) |
| +  Novel Angiogenic Therapies Using PR39 and Syndecan Proteins (BIDMC 101)
|
| +  Novel Gene Therapy Target for Cancer and Proliferative Retinopathies (BIDMC 1264) |
| +  Novel Prostate Cancer Immunotherapies (BIDMC 1187)
|
| +  Peptide Analogues of Parathyroid Hormone and PTH-related Protein (BIDMC 694) |
| +  Targeted Combination Therapy and Companion Diagnostic for Treatment of Cancers Driven by RAS (BIDMC 1223) |
| +  Use of DHA to treat Cystic Fibrosis (BIDMC 41) |
Category: Therapeutics - Methods |
| +  A Method for Inhibiting Complement Activation during Organ Transplantation (BIDMC 623) |
| +  A Nonsurgical Method for Repairing Damaged Cartilage In the Knee (BIDMC 838) |
| +  Angiogenesis Inhibition Via Thrombin Protease Activity (BIDMC 684) |
| +  Method and Apparatus for Recording an Electroencephalogram During Transcranial Magnetic Stimulation (BIDMC 55)
|
| +  Methods and Compounds for Prevention of Tissue Graft Rejection (BIDMC 244) |
| +  Stem Cell Therapy for Basement Membrane Diseases (BIDMC 905) |